Table of Content

1. Key Insights

2. Executive Summary of Osteosarcoma

3. Osteosarcoma Market Overview at a Glance
3.1. Market Share (%) distribution by Country of Osteosarcoma in 2017
3.2. Market Share (%) distribution by Country of Osteosarcoma in 2030

4. Disease Background and Overview: Osteosarcoma (OS)
4.1. Introduction
4.2. Classification of Osteosarcoma
4.3. Symptoms
4.4. Causes and risk factors
4.5. Pathogenesis of Osteosarcoma
4.6. Biomarkers
4.7. Diagnosis
4.7.1. Diagnostic Algorithm
4.7.2. Staging of Osteosarcoma
4.7.3. Diagnostic Guidelines

5. Case Reports
5.1. Locally advanced osteosarcoma of the ethmoid sinus: A report of successful management
5.2. Very late relapse of high-grade osteosarcoma: A case report and review of the literature
5.3. Case report of maxillary osteosarcoma with up-to date review

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology
6.3. Total Incident Cases of Osteosarcoma in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Incident Cases of Osteosarcoma in the United States
7.3. Gender-specific Incident Cases of Osteosarcoma in the United States
7.4. Age-specific Incident Cases of Osteosarcoma in the United States
7.5. Stage-specific Incident Cases of Osteosarcoma in the United States
7.6. Sub-types specific Incident Cases of Osteosarcoma in the United States
7.7. Site-specific Incident Cases of Osteosarcoma in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Incident Cases of Osteosarcoma in Germany
8.1.3. Gender-specific Incident Cases of Osteosarcoma in Germany
8.1.4. Age-specific Incident Cases of Osteosarcoma in Germany
8.1.5. Stage-specific Incident Cases of Osteosarcoma in Germany
8.1.6. Sub-types specific Incident Cases of Osteosarcoma in Germany
8.1.7. Site-specific Incident Cases of Osteosarcoma in Germany
8.2. France Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Total Incident Cases of Osteosarcoma in France
8.2.3. Gender-specific Incident Cases of Osteosarcoma in France
8.2.4. Age-specific Incident Cases of Osteosarcoma in France
8.2.5. Stage-specific Incident Cases of Osteosarcoma in France
8.2.6. Sub-types specific Incident Cases of Osteosarcoma in France
8.2.7. Site-specific Incident Cases of Osteosarcoma in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Incident Cases of Osteosarcoma in Italy
8.3.3. Gender-specific Incident Cases of Osteosarcoma in Italy
8.3.4. Age-specific Incident Cases of Osteosarcoma in Italy
8.3.5. Stage-specific Incident Cases of Osteosarcoma in Italy
8.3.6. Sub-types specific Incident Cases of Osteosarcoma in Italy
8.3.7. Site-specific Incident Cases of Osteosarcoma in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Incident Cases of Osteosarcoma in Spain
8.4.3. Gender-specific Incident Cases of Osteosarcoma in Spain
8.4.4. Age-specific Incident Cases of Osteosarcoma in Spain
8.4.5. Stage-specific Incident Cases of Osteosarcoma in Spain
8.4.6. Sub-types specific Incident Cases of Osteosarcoma in Spain
8.4.7. Site-specific Incident Cases of Osteosarcoma in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Incident Cases of Osteosarcoma in the United Kingdom
8.5.3. Gender-specific Incident Cases of Osteosarcoma in the United Kingdom
8.5.4. Age-specific Incident Cases of Osteosarcoma in the United Kingdom
8.5.5. Stage-specific Incident Cases of Osteosarcoma in the United Kingdom
8.5.6. Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom
8.5.7. Site-specific Incident Cases of Osteosarcoma in the United Kingdom

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Incident Cases of Osteosarcoma in Japan
9.3. Gender-specific Incident Cases of Osteosarcoma in Japan
9.4. Age-specific Incident Cases of Osteosarcoma in Japan
9.5. Stage-specific Incident Cases of Osteosarcoma in Japan
9.6. Sub-types specific Incident Cases of Osteosarcoma in Japan
9.7. Site-specific Incident Cases of Osteosarcoma in Japan

10. Treatment of Osteosarcoma
10.1. Treatment Algorithm
10.2. Treatment Guidelines
10.2.1. Nation Comprehensive Cancer Network (NCCN) guidelines for osteosarcoma
10.2.2. ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment, and follow-up
10.2.3. UK guidelines for the management of bone sarcomas

11. Unmet Needs

12. Marketed Drugs
12.1. Mepact (Mifamurtide): Takeda
12.1.1. Drug Description
12.1.2. Regulatory Milestones
12.1.3. Advantages and Disadvantages
12.1.4. Clinical Development
12.1.5. Clinical Trial Information
12.1.6. Safety and Efficacy
12.1.7. Product Profile
12.2. Khapzory (levoleucovorin): Acrotech Biopharma
12.2.1. Drug Description
12.2.2. Regulatory Milestones
12.2.3. Advantages and Disadvantages
12.2.4. Clinical Development
12.2.5. Safety and Efficacy
12.2.6. Product Profile

13. Emerging Drugs
13.1. Key cross Competition
13.2. Regorafenib: Bayer
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.3.1.1. Clinical Trials Information
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Cabozantinib S-malate: Exelixis
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.3.1. Clinical Trials Information
13.3.4. Safety and Efficacy
13.3.5. Product Profile
13.4. Bempegaldesleukin (NKTR-214): Nektar Therapeutics
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.3.1. Clinical Trials Information
13.4.4. Safety and Efficacy
13.4.5. Product Profile
13.5. Lenvatinib in Combination with Ifosfamide and Etoposide: Eisai
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.3.1. Clinical Trials Information
13.5.4. Safety and Efficacy
13.5.5. Product Profile
13.6. Danyelza (Naxitamab/Hu3F8): Y-mAbs Therapeutics
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.3.1. Clinical Trials Information
13.6.4. Safety and Efficacy
13.6.5. Product Profile
13.7. Pazopanib Hydrochloride (GW786034B/Votrient) and Topotecan Hydrochloride (Hycamtin): GlaxoSmithKline/Novartis
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.3.1. Clinical Trials Information
13.7.4. Safety and Efficacy
13.7.5. Product Profile
13.8. Nab-rapamycin (ABI-009) with Nivolumab: Aadi Bioscience
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.3.1. Clinical Trials Information
13.8.4. Safety and Efficacy
13.8.5. Product Profile
13.9. Pepinemab (VX15/2503): Vaccinex, Inc.
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.3.1. Clinical Trials Information
13.9.4. Safety and Efficacy
13.9.5. Product Profile
13.10. Nivolumab With or Without Ipilimumab: National Cancer Institute/Assaf-Harofeh Medical Center
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.3.1. Clinical Trials Information
13.10.4. Safety and Efficacy
13.10.5. Product Profile
13.11. Inhaled Lipid-complexed Cisplatin (ILC): Eleison Pharmaceuticals
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.11.3.1. Clinical Trials Information
13.11.4. Product Profile
13.12. Aliqopa (Copanlisib, BAY80-6946): Bayer
13.12.1. Product Description
13.12.2. Other Developmental Activities
13.12.3. Clinical Development
13.12.3.1. Clinical Trials Information
13.12.4. Product Profile
13.13. AU101: Aurora biopharma
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.3.1. Clinical Trials Information
13.13.4. Safety and Efficacy
13.13.5. Product Profile
13.14. CAB-AXL-ADC (BA3011): BioAtla
13.14.1. Product Description
13.14.2. Other Developmental Activities
13.14.3. Clinical Development
13.14.3.1. Clinical Trials Information
13.14.4. Product Profile
13.15. LN-145 (Autologous tumor-infiltrating lymphocytes): Iovance Biotherapeutics
13.15.1. Product Description
13.15.2. Other Developmental Activities
13.15.3. Clinical Development
13.15.3.1. Clinical Trials Information
13.15.4. Product Profile
13.16. Arfolitixorin (Modufolin): Isofol Medical AB
13.16.1. Product Description
13.16.2. Other Developmental Activities
13.16.3. Clinical Development
13.16.3.1. Clinical Trials Information
13.16.4. Product Profile
13.17. Opdivo (nivolumab): Bristol-Myers Squibb
13.17.1. Product Description
13.17.2. Other Developmental Activities
13.17.3. Clinical Development
13.17.3.1. Clinical Trials Information
13.17.4. Product Profile
13.18. CB-103: Cellestia Biotech
13.18.1. Product Description
13.18.2. Other Developmental Activities
13.18.3. Clinical Development
13.18.3.1. Clinical Trials Information
13.18.4. Product Profile

14. Osteosarcoma: Seven Major Market Analysis
14.1. Key Findings
14.2. Market Methodology
14.3. Attribute Analysis
14.4. Market Size of Osteosarcoma in the 7MM
14.5. Market Size of Osteosarcoma in the 7MM by Therapies

15. Key Market Forecast Assumptions

16. 7MM Market Outlook
16.1. The United States Market Size
16.1.1. Total Market size of Osteosarcoma
16.1.2. Market Size by Therapies
16.1.3. Market Size of Osteosarcoma by Line of Therapies
16.1.3.1. Market Size of Osteosarcoma (Non-Metastatic)
16.1.3.2. Market Size of Osteosarcoma (Metastatic)

17. EU5
17.1. Germany Market Size
17.1.1. Total Market Size of Osteosarcoma
17.1.2. Market Size by Therapies
17.1.3. Market Size of Osteosarcoma by Line of Therapies
17.1.3.1. Market Size of Osteosarcoma (Non-Metastatic)
17.1.3.2. Market Size of Osteosarcoma (Metastatic)
17.2. France Market Size
17.2.1. Total Market Size of Osteosarcoma
17.2.2. Market Size by Therapies
17.2.3. Market Size of Osteosarcoma by Line of Therapies
17.2.3.1. Market Size of Osteosarcoma (Non-Metastatic)
17.2.3.2. Market Size of Osteosarcoma (Metastatic)
17.3. Italy Market Size
17.3.1. Total Market size of Osteosarcoma
17.3.2. Market Size by Therapies
17.3.3. Market Size of Osteosarcoma by Line of Therapies
17.3.3.1. Market Size of Osteosarcoma (Non-Metastatic)
17.3.3.2. Market Size of Osteosarcoma (Metastatic)
17.4. Spain Market Size
17.4.1. Total Market size of Osteosarcoma
17.4.2. Market Size by Therapies
17.4.3. Market Size of Osteosarcoma by Line of Therapies
17.4.3.1. Market Size of Osteosarcoma (Non-Metastatic)
17.4.3.2. Market Size of Osteosarcoma (Metastatic)
17.5. The United Kingdom Market Size
17.5.1. Total Market size of Osteosarcoma
17.5.2. Market Size by Therapies
17.5.3. Market Size of Osteosarcoma by Line of Therapies
17.5.3.1. Market Size of Osteosarcoma (Non-Metastatic)
17.5.3.2. Market Size of Osteosarcoma (Metastatic)

18. Japan
18.1. Japan Market Size
18.1.1. Total Market size of Osteosarcoma
18.1.2. Market Size by Therapies
18.1.3. Market Size of Osteosarcoma by Line of Therapies
18.1.3.1. Market Size of Osteosarcoma (Non-Metastatic)
18.1.3.2. Market Size of Osteosarcoma (Metastatic)

19. Market Drivers

20. Market Barriers
21. SWOT Analysis
22. Reimbursement and Market Access
23. KOL Views
24. Appendix
24.1. Bibliography
24.2. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight



List of Figures


Figure 1 Biologic growth pattern of osteosarcomas
Figure 2 Symptoms of osteosarcoma
Figure 3 Risk factors of osteosarcoma
Figure 4 Epigenetic events which may contribute to the initiation and progression of OS
Figure 5 Participation of microRNAs (miRs) in OS development
Figure 6 Role of lncRNAs and circRNAs in osteosarcoma
Figure 7 General diagnostic strategy for bone sarcomas
Figure 8 Total Incident Cases of Osteosarcoma in the 7MM (2017–2030)
Figure 9 Total Incident cases of Osteosarcoma in the US (2017–2030)
Figure 10 Gender-specific Incident cases of Osteosarcoma in the US (2017–2030)
Figure 11 Age-specific Incident Cases of Osteosarcoma in the US (2017–2030)
Figure 12 Stage-specific Incident Cases of Osteosarcoma in the US (2017–2030)
Figure 13 Sub-types specific Incident Cases of Osteosarcoma in the US (2017–2030)
Figure 14 Site-specific Incident Cases of Osteosarcoma in the US (2017–2030)
Figure 15 Total Incident cases of Osteosarcoma in Germany (2017–2030)
Figure 16 Gender-specific Incident cases of Osteosarcoma in Germany (2017–2030)
Figure 17 Age-specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Figure 18 Stage-specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Figure 19 Sub-types specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Figure 20 Site-specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Figure 21 Total Incident cases of Osteosarcoma in France (2017–2030)
Figure 22 Gender-specific Incident cases of Osteosarcoma in France (2017–2030)
Figure 23 Age-specific Incident Cases of Osteosarcoma in France (2017–2030)
Figure 24 Stage-specific Incident Cases of Osteosarcoma in France (2017–2030)
Figure 25 Sub-types specific Incident Cases of Osteosarcoma in France (2017–2030)
Figure 26 Site-specific Incident Cases of Osteosarcoma in France (2017–2030)
Figure 27 Total Incident cases of Osteosarcoma in Italy (2017–2030)
Figure 28 Gender-specific Incident cases of Osteosarcoma in Italy (2017–2030)
Figure 29 Age-specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Figure 30 Stage-specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Figure 31 Sub-types specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Figure 32 Site-specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Figure 33 Total Incident cases of Osteosarcoma in Spain (2017–2030)
Figure 34 Gender-specific Incident cases of Osteosarcoma in Spain (2017–2030)
Figure 35 Age-specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Figure 36 Stage-specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Figure 37 Sub-types specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Figure 38 Site-specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Figure 39 Total Incident cases of Osteosarcoma in the United Kingdom (2017–2030)
Figure 40 Gender-specific Incident cases of Osteosarcoma in the United Kingdom (2017–2030)
Figure 41 Age-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Figure 42 Stage-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Figure 43 Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Figure 44 Site-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Figure 45 Total Incident cases of Osteosarcoma in Japan (2017–2030)
Figure 46 Gender-specific Incident cases of Osteosarcoma in Japan (2017–2030)
Figure 47 Age-specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Figure 48 Stage-specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Figure 49 Sub-types specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Figure 50 Site-specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Figure 51 Diagnostic and therapeutic algorithm of osteosarcoma
Figure 52 Unmet needs of Osteosarcoma
Figure 53 Seven Major Market Size of Osteosarcoma in USD Million (2017–2030)
Figure 54 Seven Major Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Figure 55 Market Size of Osteosarcoma in the United States, USD Million (2017–2030)
Figure 56 United States Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Figure 57 United States Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Figure 58 United States Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Figure 59 Market Size of Osteosarcoma in Germany, USD Million (2017–2030)
Figure 60 Germany Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Figure 61 Germany Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Figure 62 Germany Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Figure 63 Market Size of Osteosarcoma in France, USD Million (2017–2030)
Figure 64 France Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Figure 65 France Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Figure 66 France Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Figure 67 Market Size of Osteosarcoma in Italy, USD Million (2017–2030)
Figure 68 Italy Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Figure 69 Italy Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Figure 70 Italy Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Figure 71 Market Size of Osteosarcoma in Spain, USD Million (2017–2030)
Figure 72 Spain Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Figure 73 Spain Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Figure 74 Spain Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Figure 75 Market Size of Osteosarcoma in the United Kingdom, USD Million (2017–2030)
Figure 76 United Kingdom Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Figure 77 United Kingdom Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Figure 78 United Kingdom Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Figure 79 Market Size of Osteosarcoma in Japan, USD Million (2017–2030)
Figure 80 Japan Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Figure 81 Japan Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Figure 82 Japan Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Figure 83 Market Drivers
Figure 84 Market Barriers
Figure 85 SWOT analysis
Figure 86 Summary of Takeda UK Mifamurtide Patient Access Scheme

 

List of Tables


Table 1 Summary of Osteosarcoma, Market, Epidemiology and Key Events (2017–2030)
Table 2 Enneking MSTS staging system
Table 3 AJCC staging system for bone sarcoma
Table 4 Total Incident Cases of Osteosarcoma in the 7MM (2017–2030)
Table 5 Total Incident Cases of Osteosarcoma in the US (2017–2030)
Table 6 Gender-specific Incident Cases of Osteosarcoma in the US (2017–2030)
Table 7 Age-specific Incident Cases of Osteosarcoma in the US (2017–2030)
Table 8 Stage-specific Incident Cases of Osteosarcoma in the US (2017–2030)
Table 9 Sub-types specific Incident Cases of Osteosarcoma in the US (2017–2030)
Table 10 Site-specific Incident Cases of Osteosarcoma in the US (2017–2030)
Table 11 Total Incident Cases of Osteosarcoma in Germany (2017–2030)
Table 12 Gender-specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Table 13 Age-specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Table 14 Stage-specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Table 15 Sub-types specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Table 16 Site-specific Incident Cases of Osteosarcoma in Germany (2017–2030)
Table 17 Total Incident Cases of Osteosarcoma in France (2017–2030)
Table 18 Gender-specific Incident Cases of Osteosarcoma in France (2017–2030)
Table 19 Age-specific Incident Cases of Osteosarcoma in France (2017–2030)
Table 20 Stage-specific Incident Cases of Osteosarcoma in France (2017–2030)
Table 21 Sub-types specific Incident Cases of Osteosarcoma in France (2017–2030)
Table 22 Site-specific Incident Cases of Osteosarcoma in France (2017–2030)
Table 23 Total Incident Cases of Osteosarcoma in Italy (2017–2030)
Table 24 Gender-specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Table 25 Age-specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Table 26 Stage-specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Table 27 Sub-types specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Table 28 Site-specific Incident Cases of Osteosarcoma in Italy (2017–2030)
Table 29 Total Incident Cases of Osteosarcoma in Spain (2017–2030)
Table 30 Gender-specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Table 31 Age-specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Table 32 Stage-specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Table 33 Sub-types specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Table 34 Site-specific Incident Cases of Osteosarcoma in Spain (2017–2030)
Table 35 Total Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Table 36 Gender-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Table 37 Age-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Table 38 Stage-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Table 39 Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Table 40 Site-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)
Table 41 Total Incident Cases of Osteosarcoma in Japan (2017–2030)
Table 42 Gender-specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Table 43 Age-specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Table 44 Stage-specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Table 45 Sub-types specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Table 46 Site-specific Incident Cases of Osteosarcoma in Japan (2017–2030)
Table 47 Osteosarcoma systemic therapy agents of the NCCN guidelines
Table 48 MAP chemotherapy schedule
Table 49 Systemic therapy agents for osteosarcoma
Table 50 Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System)
Table 51 Sarcoma advisory group guidelines for osteosarcoma
Table 52 Mifamurtide, Clinical Trial Description, 2020
Table 53 Comparison of emerging drugs under development
Table 54 Regorafenib, Clinical Trial Description, 2020
Table 55 Cabozantinib S-malate, Clinical Trial Description, 2020
Table 56 Bempegaldesleukin, Clinical Trial Description, 2020
Table 57 Lenvatinib in Combination With Ifosfamide and Etoposide, Clinical Trial Description, 2020
Table 58 Danyelza (Naxitamab/Hu3F8), Clinical Trial Description, 2020
Table 59 Pazopanib Hydrochloride in combination with Topotecan Hydrochloride, Clinical Trial Description, 2020
Table 60 Nab-rapamycin (ABI-009) with Nivolumab, Clinical Trial Description, 2020
Table 61 Pepinemab, Clinical Trial Description, 2020
Table 62 Nivolumab With or Without Ipilimumab, Clinical Trial Description, 2020
Table 63 Inhaled Lipid-complexed Cisplatin, Clinical Trial Description, 2020
Table 64 Aliqopa (copanlisib, BAY80-6946), Clinical Trial Description, 2020
Table 65 AU101, Clinical Trial Description, 2020
Table 66 CAB-AXL-ADC (BA3011), Clinical Trial Description, 2020
Table 67 LN-145, Clinical Trial Description, 2020
Table 68 Arfolitixorin (Modufolin), Clinical Trial Description, 2020
Table 69 Nivolumab, Clinical Trial Description, 2020
Table 70 CB-103, Clinical Trial Description, 2020
Table 71 Seven Major Market Size of Osteosarcoma in USD Million (2017–2030)
Table 72 7 Major Market Size of Osteosarcoma by therapies in USD Million (2017–2030)
Table 73 Key Market Forecast Assumptions for Lenvatinib
Table 74 Key Market Forecast Assumptions for Regorafenib
Table 75 Key Market Forecast Assumptions for Cabozantinib S-malate
Table 76 Key Market Forecast Assumptions for Pazopanib Hydrochloride
Table 77 Key Market Forecast Assumptions for Bempegaldesleukin
Table 78 Market Size of Osteosarcoma in the United States, USD Million (2017–2030)
Table 79 United States Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Table 80 United States Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Table 81 United States Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Table 82 Market Size of Osteosarcoma in Germany, USD Million (2017–2030)
Table 83 Germany Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Table 84 Germany Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Table 85 Germany Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Table 86 Market Size of Osteosarcoma in France, USD Million (2017–2030)
Table 87 France Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Table 88 France Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Table 89 France Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Table 90 Market Size of Osteosarcoma in Italy, USD Million (2017–2030)
Table 91 Italy Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Table 92 Italy Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Table 93 Italy Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Table 94 Market Size of Osteosarcoma in Spain, USD Million (2017–2030)
Table 95 Spain Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Table 96 Spain Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Table 97 Spain Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Table 98 Market Size of Osteosarcoma in the United Kingdom, USD Million (2017–2030)
Table 99 United Kingdom Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Table 100 United Kingdom Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Table 101 United Kingdom Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)
Table 102 Market Size of Osteosarcoma in Japan, USD Million (2017–2030)
Table 103 Japan Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)
Table 104 Japan Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)
Table 105 Japan Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)